Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Aug 26, 2021 10:32am
118 Views
Post# 33766922

RE:Pfizer taps McKinsey veteran Malik as new dealmaking czar

RE:Pfizer taps McKinsey veteran Malik as new dealmaking czar
Jun 16, 2021 Mckinsey Virtual meeting :  New Approaches to I/O With Innovative Partnership Models"It Takes a Village: New Approaches to I/O with Innovative Partnership Models
"Collaboration among industry stakeholders is essential to discovering and developing emerging I/O approaches – where many see a promise in revolutionizing treatments for all types of cancer. 

In 2020, despite the challenges of the COVID-19 pandemic, immuno-oncology assets represented 49% of oncology licensing transactions (out of a total value of $56B, Nature) and 66% of total disclosed deal value (out of a total value of $133B, Nature).

With new partnerships and deals being announced on a near-daily basis, 2021 appears to be staying on trend.."
<< Previous
Bullboard Posts
Next >>